Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Hui · SciRah

Researcher profile · Semantic Scholar

A. Hui

Share profile

A. Hui — researcher profile on SciRah

h-index: 28
Works: 81
Citations: 4,410

Most-cited papers

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
P. Moreau, T. Masszi, N. Grząśko, N. Bahlis +22 more
2016New England Journal of Medicine988 citations Open access
Semantic Scholar
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain.
Li-Xin Sun, A. Hui, Q. Su, A. Vortmeyer +9 more
2006Cancer Cell874 citations Open access
Semantic Scholar
Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients
L. Kenny, R. Coombes, I. Oulie, K. Contractor +11 more
2008Journal of Nuclear Medicine293 citations Open access
Semantic Scholar
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Shaji K. Kumar, J. Berdeja, R. Niesvizky, S. Lonial +15 more
2014The Lancet Oncology242 citations
Semantic Scholar
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
P. Richardson, R. Baz, Michael L. Wang, A. Jakubowiak +10 more
2014Blood203 citations Open access
Semantic Scholar
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Shaji K. Kumar, W. Bensinger, T. Zimmerman, C. Reeder +8 more
2014Blood195 citations Open access
Semantic Scholar
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study
Jingxin Li, A. Hui, Xiang Zhang, Yumei Yang +18 more
2021Nature Medicine114 citations Open access
Semantic Scholar
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
V. Sanchorawala, G. Palladini, V. Kukreti, J. Zonder +11 more
2017Blood112 citations Open access
Semantic Scholar
The Biodistribution and Radiation Dosimetry of the Arg-Gly-Asp Peptide 18F-AH111585 in Healthy Volunteers
B. McParland, Matthew P. Miller, T. Spinks, L. Kenny +6 more
2008Journal of Nuclear Medicine76 citations Open access
Semantic Scholar
Agents with Selective Estrogen Receptor (ER) Modulator Activity Induce Apoptosis In vitro and In vivo in ER-Negative Glioma Cells
A. Hui, Wei Zhang, Wei R. Chen, Dan Xi +3 more
2004Cancer Research76 citations
Semantic Scholar
Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)
P. Moreau, T. Masszi, N. Grząśko, N. Bahlis +21 more
201575 citations
Semantic Scholar
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.
P. Richardson, M. Attal, F. Campana, Solenn Le-Guennec +4 more
2018Future Oncology70 citations Open access
Semantic Scholar
The Delivery of mRNA Vaccines for Therapeutics
Nitika, Jiao Wei, A. Hui
2022Life64 citations Open access
Semantic Scholar
Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
N. Gupta, Yuan Zhao, A. Hui, D. Esseltine +1 more
2015British Journal of Clinical Pharmacology57 citations Open access
Semantic Scholar
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis
N. Gupta, M. Hanley, R. D. Harvey, A. Badros +9 more
2016British Journal of Haematology52 citations Open access
Semantic Scholar
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Jiao Wei, A. Hui
2022Cancer Treatment Reviews51 citations Open access
Semantic Scholar
Role of Biomarkers in FLT3 AML
Nitika, Jiao Wei, A. Hui
2022Cancers47 citations Open access
Semantic Scholar
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
S. Assouline, Julie E. Chang, B. Cheson, R. Rifkin +8 more
2014Blood Cancer Journal47 citations Open access
Semantic Scholar
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
David C. Smith, T. Kalebic, J. Infante, L. Siu +13 more
2015Investigational new drugs42 citations Open access
Semantic Scholar
A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)
Shaji K. Kumar, J. Berdeja, R. Niesvizky, S. Lonial +11 more
201142 citations
Semantic Scholar
The patient’s perspective on the symptom and everyday life impact of AL amyloidosis
H. Lin, D. Seldin, A. Hui, D. Berg +2 more
2015Amyloid: Journal of Protein Folding Disorders39 citations
Semantic Scholar
The Effect of a High‐Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma
N. Gupta, M. Hanley, K. Venkatakrishnan, Bingxia Wang +4 more
2016Journal of clinical pharmacology38 citations Open access
Semantic Scholar
Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data
C. Hofmeister, C. Rosenbaum, M. Htut, D. Vesole +12 more
201338 citations
Semantic Scholar
Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
N. Gupta, Y. Goh, C. Min, J. H. Lee +9 more
2015Journal of Hematology & Oncology37 citations Open access
Semantic Scholar
The Development of mRNA Vaccines for Infectious Diseases: Recent Updates
Nitika, Jiao Wei, A. Hui
2021Infection and Drug Resistance34 citations Open access
Semantic Scholar
Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study
P. Richardson, R. Baz, Lu-Hua Wang, A. Jakubowiak +6 more
201132 citations
Semantic Scholar
The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
B. Ruggeri, S. Miknyoczki, B. Dorsey, A. Hui
2009Advances in Pharmacology32 citations
Semantic Scholar
Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results
Shaji K. Kumar, J. Berdeja, R. Niesvizky, S. Lonial +12 more
201430 citations
Semantic Scholar
The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
P. Richardson, P. Moreau, J. Laubach, N. Gupta +4 more
2015Future Oncology28 citations
Semantic Scholar
Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): A phase I/II study.
P. Richardson, J. Berdeja, R. Niesvizky, S. Lonial +8 more
201226 citations
Semantic Scholar
Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma
T. Martin, G. Mannis, A. Chari, P. Munster +3 more
201625 citations
Semantic Scholar
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients
N. Gupta, Y. Huh, M. Hutmacher, S. Ottinger +2 more
2015Cancer Chemotherapy and Pharmacology24 citations
Semantic Scholar
Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study
Shaji K. Kumar, W. Bensinger, C. Reeder, T. Zimmerman +7 more
201123 citations
Semantic Scholar
Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study
N. Gupta, R. Labotka, Guo-Hui Liu, A. Hui +1 more
2016Investigational new drugs21 citations Open access
Semantic Scholar
Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)
G. Merlini, V. Sanchorawala, Z. Jeffrey, V. Kukreti +9 more
201420 citations Open access
Semantic Scholar
MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study
G. Merlini, V. Sanchorawala, J. Zonder, V. Kukreti +11 more
201220 citations
Semantic Scholar
Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM).
S. Lonial, R. Baz, Michael L. Wang, M. Talpaz +6 more
201218 citations
Semantic Scholar
Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment.
Shaji K. Kumar, W. Bensinger, T. Zimmerman, C. Reeder +8 more
201317 citations
Semantic Scholar
A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.
N. Gabrail, E. Hamilton, A. Elias, M. Rimawi +9 more
Journal of Clinical Oncology15 citations
Semantic Scholar
Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas
Xiao-Jie Hu, Wen-Bin Li, K. Zeng, Zhongyuan Xu +13 more
2023BMC Medicine14 citations Open access
Semantic Scholar
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.
L. Mao, Jun Guo, Lingjun Zhu, Yu Jiang +10 more
2022European Journal of Cancer14 citations Open access
Semantic Scholar
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial
A. Hui, Jingxin Li, Li Zhu, R. Tang +28 more
2022The Lancet Regional Health - Western Pacific14 citations Open access
Semantic Scholar
Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)
M. Dimopoulos, S. Grosicki, W. Jędrzejczak, H. Nahi +7 more
201514 citations
Semantic Scholar
Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study.
Shaji K. Kumar, W. Bensinger, C. Reeder, T. Zimmerman +7 more
201213 citations
Semantic Scholar
Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma
S. Assouline, Julie E. Chang, B. Cheson, R. Rifkin +8 more
201211 citations
Semantic Scholar
SAF-189s in previously treated patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC): Results from the dose-finding portion in a single-arm, first-in-human phase I/II study.
Jin-Ji Yang, Jian-Ying Zhou, N. Yang, Zhuli Wu +3 more
202010 citations
Semantic Scholar
SAF-189s in advanced, ALK-positive, non–small cell lung cancer: Results from a first-in-human phase 1/2, multicenter study.
Jin-Ji Yang, Jian-Ying Zhou, Ying Cheng, Ming-Jun Li +11 more
2022Journal of Clinical Oncology9 citations
Semantic Scholar
Avatrombopag ethnic sensitivity analysis in chronic liver disease and thrombocytopenia patients: individual-level pooled analysis
Jun Lu, B. Jamieson, A. Hui
2022Therapeutic Advances in Gastroenterology7 citations Open access
Semantic Scholar
Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis
N. Gupta, M. Hanley, R. Harvey, A. Badros +8 more
20157 citations
Semantic Scholar
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial
Jingxin Li, A. Hui, Xiang Zhang, Lei Ge +26 more
2022Advances in Therapy6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Gupta×24
Invite
N. Gupta — researcher profile on SciRah
D. Berg×19
Invite
D. Berg — researcher profile on SciRah
Alessandra Di Bacco×15
Invite
Alessandra Di Bacco — researcher profile on SciRah
Shaji K. Kumar×9
Invite
Shaji K. Kumar — researcher profile on SciRah

×9

Invite

Guo-Hui Liu — researcher profile on SciRah

P. Richardson×8

Invite

P. Richardson — researcher profile on SciRah

R. Niesvizky×8

Invite

R. Niesvizky — researcher profile on SciRah

Invite

J. Berdeja — researcher profile on SciRah

Invite

S. Lonial — researcher profile on SciRah

K. Venkatakrishnan×7

Invite

K. Venkatakrishnan — researcher profile on SciRah

Invite

Jiang Yu — researcher profile on SciRah

Invite

V. Kukreti — researcher profile on SciRah